NAVAMEDIC ASA Oslo ,15 February 2024 -Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent toNOK 512 million , mainly by organic growth. For the first time all three product categories were above theNOK 100 million mark. The company's gross margin was 38.9 per cent for the year, down from 42.8 per cent in the year before. Adjusted EBITDA (EBITDA less acquisition cost) amounted toNOK 51.6 million , compared withNOK 51.7 million in 2022. Operating results (EBIT) amounted toNOK 23.6 million , compared toNOK 44.4 million in 2022. Operating costs were higher than in 2022, mostly due to continued investments in growth initiatives. Also included in the EBITDA is a negative contribution of 4.8 MNOK from theSensidose business. "We are looking back at an eventful and transformative year. With theSensidose acquisition, we gained a promising position in the market for treatment of Parkinson's Disease, and we renewed and secured new marketing and distribution agreements for several other high selling products, including Eroxon®, a clinically proven treatment of erectile dysfunction. Eroxon® was launched inNorway this week and will soon also be available inSweden ," saidKathrine Gamborg Andreassen , CEO ofNavamedic . "Furthermore, in the fourth quarter 2023, we signed a term sheet with the Finnish pharmaceutical corporationOrion Pharma , which we are currently finalising into an agreement for a licensing and supply of Flexilev® and OraFID® inEurope , products that were acquired throughSensidose . InSweden ,Norway andDenmark , we will market and sell these products from our own proven platform," Andreassen added. Revenues in the fourth quarter of 2023 wasNOK 125 million , up 8.1 percent from the same period last year. Gross margin was 36.5 per cent, down from 42.9 per cent, and Adjusted EBITDA wasNOK 7.9 million , compared withNOK 15.7 million in the fourth quarter of 2022. Category update In theConsumer Health category, Modifast cemented its position with continued strong sales inSweden , and Absolute Torr gained traction with a 54 per cent growth year-over-year in the fourth quarter. Further growth to be achieved through combination of consumer and pharmacy engagement, sale of unique and profitable products in home markets and out-licensing of own products elsewhere. The Hospital category saw double-digit growth year-over-year across the portfolio of antibiotics and medical nutrition products. It also renewed exclusive rights toVitaflo's medical nutrition products across the Nordic for five more years. Winning new antibiotic tenders is core in the growth strategy, along with initiatives to expand and secure new marketing authorisations. The Prescription Drugs category had strong growth across various therapeutic areas, with continued high demand for Mysimba for obesity treatment, and strong sales of Imdur, Nitrolingual and Forlax. In this category,Navamedic is now preparing rollout of Flexilev with MyFID® and OraFID® in the Nordic countries and out-licensing in the rest ofEurope . OutlookNavamedic sees continued strong growth and new expansion opportunities and reiterates its mid-term ambition of building aNOK 1 billion revenue company with a 15 per cent EBITDA margin. "We are building on a solid foundation. We will continue to strengthen our existing business by leveraging our highly scalable market access platform. We will explore opportunities for market expansion with own products and increase company value by acquiring and strengthening own products and brands while increasing gross margins through careful management of our product portfolio," Andreassen concluded.Navamedic will present the results for the fourth quarter and full year 2023 at 08.30 today. The presentation will take place at Dronning Eufemias Gate 16 inOslo , and will be available to follow via webcast at the following link: https://navamedic.com/investors/financial-results/ Representatives fromNavamedic's management team, CEOKathrine Gamborg Andreassen and CFOLars Hjarrand will host the presentation. EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section of the attached presentation on slide 23. For further information, please contact:Kathrine Gamborg Andreassen , CEO,Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO,Navamedic Mobile: +47917 62 842 E-mail: lars.hjarrand@navamedic.com AboutNavamedic Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies.Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge.Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in theUK andGreece .Navamedic is headquartered inOslo, Norway , and listed on theOslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source
